Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Galmed Pharmaceuticals Ltd. (GLMD) had Return on Tangible Equity of -19.65% for the most recently reported fiscal quarter, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-3.21M |
|
-- |
|
-- |
|
$1.64M |
|
$-1.64M |
|
$-1.56M |
|
$-3.21M |
|
$-2.06M |
|
$-3.21M |
|
$-3.21M |
|
$-3.21M |
|
$-2.06M |
|
$-1.64M |
|
$-1.66M |
|
0.93M |
|
0.93M |
|
$-0.85 |
|
$-0.85 |
|
| Balance Sheet Financials | |
$16.12M |
|
-- |
|
$2.38M |
|
$18.50M |
|
$2.17M |
|
-- |
|
-- |
|
$2.17M |
|
$16.33M |
|
$16.33M |
|
$16.33M |
|
1.67M |
|
| Cash Flow Statement Financials | |
$-5.88M |
|
$-1.11M |
|
$8.79M |
|
$2.98M |
|
$4.77M |
|
$1.79M |
|
$0.53M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.42 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-5.88M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-19.65% |
|
|
Return on Tangible Equity |
-19.65% |
-17.35% |
|
-19.65% |
|
$9.81 |
|
$-6.32 |
|
$-6.32 |
|